Mindset Pharma Selects Treatment-Resistant Depression and End of Life Cancer Angst as Indications for MSP-1014, its NoveHow Will The Data Protection Ruling On Ketamine Impact Psychedelic Novel Drug Development Moving Forward?Mindset Pharma Announces its Next Generation Novel 5-MeO-DMT Psychedelic AnalogsSilo Pharma Advances Psychedelic Patent PortfolioTryp Therapeutics Completes Psychotherapy Training for Phase 2a Study at the University of FloridaMajor Psychedelic Clinical Trial Data Is Right Around The CornerPsychedelic Drug Development Companies Are Leveraging Bolt On MedTech Acquisitions To Create A More Robust Patient Care 7 Psychedelic Clinical Trials Underway That Investors Should Keep On Their RadarNuminus Wellness Closes Q3 2021 With $63.2 Million Cash Position, Lab and Trial Advances, and Strategic Expansion into PSilo Pharma Awarded Notice of Allowance from United States Patent and Trademark Office for Homing Peptide PatentTryp Therapeutics Announces Q3 2021 Financial ResultsKetamine One’s IRP Clinic Using Innovative NeuroCatch Platform to Measure Brain Function in Injured VeteransWake Network, Inc. and the Lieber Institute for Brain Development Announce Research CollaborationTryp Therapeutics Announces Plans for Phase 2a Clinical Trial for Fibromyalgia with the University of MichiganNuminus Wellness Reaches Major Milestone With MAPS Sponsored MDMA StudyNuminus Announces Health Canada Approval of MAPS-Sponsored Open Label Study for MDMA-Assisted Therapy for PTSDPsyence Group and UK Psychedelic CRO Partners to Conduct UK Palliative Care Clinical TrialTryp Therapeutics Partners with the University of Michigan to Evaluate Proprietary FormulationsPsyched Wellness Commences Next Pre-Clinical Study on AME-1Atai Life Sciences Is Setting The Standard For Psychedelic Drug Development
Back

7 Psychedelic Clinical Trials Underway That Investors Should Keep On Their Radar

Jul 30, 2021 • 5:29 AM EDT
3 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

One of the standouts of 2021 so far has been the psychedelic therapy industry and this is a market that is just starting to gain traction. 

Several leading psychedelic therapy companies are backed by big money and are in advanced stages of US Food and Drug Administration (FDA) clinical trials. We believe the vertical looks similar the cannabis biotech industry in 2016 and this is a trend that our readers need to be aware of. 

When compared to the biotech cannabis sector, there are more psychedelic therapy companies than there were in the cannabis industry. In 2016, GW Pharmaceuticals (was recent acquired by Jazz Pharmaceuticals for $220 per share) released positive data from a Phase 3 clinical trial and the stock surged higher on this development. 

Following this milestone by GW, the stock rallied more than 500% over the next few years and this performance numbers caught our attention. The feat that GW accomplished was a game-changer for the cannabis industry and we have identified 5 psychedelic therapy companies that could see a GW type rally if they report positive Phase 3 clinical trial data. We believe that our readers need to be aware of these operators and have highlighted them below:

  1. We consider COMPASS Pathways (Nasdaq: CMPS) to be one of the best positioned psychedelic therapy operators and is a mental health care company that is dedicated to accelerating patient access to evidence-based innovation in mental health. COMPASS is developing psilocybin therapy for treatment-resistant depression and we are favorable on the total addressable market (TAM) that is associated with this indication. 
  2. ATAI Life Sciences (Nasdaq: ATAI) has two separate joint ventures (JV) with DemeRx, a clinical stage pharmaceutical company that is focused on developing ibogaine and noribogaine for the treatment of opioid use disorder (OUD). ATAI and DemeRx plan to submit clinical trial applications for a Phase II study in opioid-dependence and we are favorable on this opportunity for the companies.
  3. Multidisciplinary Association for Psychedelic Studies (MAPS) was founded in 1986 and  is currently sponsoring a Phase 3 trial of MDMA-assisted psychotherapy for the treatment of PTSD. This is the world’s most advanced psychedelic program and is one of only three programs to be granted the breakthrough therapy designation (BTD) by the FDA.
  4. MindMed Inc. (NEO: MMEN) (Nasdaq: MNMD) is currently in a Phase 2a trial on LSD (experiential) for both anxiety and cluster headaches. The company is working to advance through the necessary regulatory filings to start a Phase 2a trial on LSD (microdose) for adult ADHD in the Netherlands and Switzerland
  5. Cybin (NEO: CYBN) (OTC: CLXPF) is an emerging psychedelic therapy company that is currently in the process of conducting a Phase 2a and 2b study on major depressive disorder (MDD) in Jamaica. The company has been building a portfolio of intellectually property (IP) and is an opportunity that we are following. 
  6. Tryp Therapeutics Inc. (CSE: TRYP) (OTC: TRYPF) is working to create a diversified portfolio of product candidates that target neuropsychiatric and oncology indications that have large unmet medical needs. The company is developing a PFN Program (Psilocybin-for-Neuropsychiatric) disorders and plans to go through the US FDA regulatory pathway to complete Phase 2 clinical trials and monetize their assets prior to Phase 3.
  7. Numinus Wellness Inc. (TSX Venture: NUMI)  is targeting the growing number of people who suffer from post-traumatic stress disorder (PTSD), addictions and other mental health issues. The company has a Health Canada licensed laboratory licensed to conduct research on several psychedelics substances and that can leverage psychedelic therapies for treatment resistant mental health disorders. Numinus is working to amend the license to include the production of psilocybin for research and for import and export.

If you are interested in learning more about psychedelic therapy companies, please send an email to support@technical420.com with the subject “Psychedelic Therapy Companies” to be added to our distribution list. 

 

 

 

 

SB Partners has positions in Compass Pathways (CMPS) 200 shares and Mind Medicine Inc. (MNMD) 750 shares as of 7/30 with no intent to sell.

Share Share - Facebook Share - Twitter

Tags

Authored By

Michael Berger

Comments

Top Stories

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.
Subscribe
SUBSCRIBE NOW
close-link